SPDR S&P Biotech ETF (NYSEARCA:XBI) Hits New 52-Week Low – Here’s What Happened

SPDR S&P Biotech ETF (NYSEARCA:XBI)’s share price hit a new 52-week low during trading on Monday . The stock traded as low as $69.24 and last traded at $69.72, with a volume of 2614060 shares trading hands. The stock had previously closed at $73.66.

SPDR S&P Biotech ETF Trading Down 0.9 %

The business has a fifty day moving average price of $88.13 and a two-hundred day moving average price of $93.12. The firm has a market capitalization of $4.60 billion, a PE ratio of 11.47 and a beta of 1.00.

SPDR S&P Biotech ETF Cuts Dividend

The business also recently announced a dividend, which was paid on Wednesday, March 26th. Shareholders of record on Monday, March 24th were given a $0.0053 dividend. The ex-dividend date was Monday, March 24th.

Institutional Investors Weigh In On SPDR S&P Biotech ETF

A number of institutional investors have recently made changes to their positions in the stock. Addison Advisors LLC lifted its holdings in shares of SPDR S&P Biotech ETF by 27.4% in the 4th quarter. Addison Advisors LLC now owns 535 shares of the exchange traded fund’s stock worth $48,000 after acquiring an additional 115 shares during the last quarter. Invst LLC lifted its stake in SPDR S&P Biotech ETF by 6.0% during the third quarter. Invst LLC now owns 2,807 shares of the exchange traded fund’s stock worth $277,000 after purchasing an additional 160 shares in the last quarter. Beech Hill Advisors Inc. boosted its position in shares of SPDR S&P Biotech ETF by 2.5% during the fourth quarter. Beech Hill Advisors Inc. now owns 6,655 shares of the exchange traded fund’s stock worth $599,000 after buying an additional 162 shares during the period. Wealth Alliance grew its stake in shares of SPDR S&P Biotech ETF by 4.4% in the fourth quarter. Wealth Alliance now owns 4,083 shares of the exchange traded fund’s stock valued at $368,000 after buying an additional 173 shares in the last quarter. Finally, CX Institutional raised its holdings in shares of SPDR S&P Biotech ETF by 1.6% in the 4th quarter. CX Institutional now owns 12,196 shares of the exchange traded fund’s stock valued at $1,098,000 after buying an additional 196 shares during the period.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.